We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · May 31, 2020

Assessment of Immunogenicity From Galcanezumab Phase III Trials in Patients With Episodic or Chronic Migraine

Cephalalgia: An International Journal of Headache

 

Additional Info

Disclosure statements are available on the authors' profiles:

Cephalalgia: An International Journal of Headache
Assessment of Immunogenicity From Galcanezumab Phase 3 Trials in Patients With Episodic or Chronic Migraine
Cephalalgia 2020 Apr 27;[EPub Ahead of Print], JM Martinez, N Hindiyeh, G Anglin, K Kalidas, ME Hodsdon, W Kielbasa, BA Moser, EM Pearlman, S Garces

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading